| Market Capitalization (Millions $) |
15,156 |
| Shares
Outstanding (Millions) |
450 |
| Employees |
200 |
| Revenues (TTM) (Millions $) |
2,264 |
| Net Income (TTM) (Millions $) |
1,331 |
| Cash Flow (TTM) (Millions $) |
452 |
| Capital Exp. (TTM) (Millions $) |
0 |
Royalty Pharma Plc
Royalty Pharma Plc is a pharmaceutical company that specializes in acquiring and managing royalty interests in innovative biopharmaceutical products. Established in 1996, the company has since grown to become the largest buyer of biopharmaceutical royalties in the world.
As a business model, Royalty Pharma does not engage in the research, development, or commercialization of new drugs. Instead, the company acquires the rights to receive future royalties from the sale of existing therapies. In doing so, it provides a valuable source of financing for drug developers and manufacturers, while also generating revenue through the collection of these royalties.
The company's portfolio includes approximately 50 different products that are sold around the world. These products are primarily used in the treatment of cancer, immunological disorders, infectious diseases, and rare genetic disorders. Some of the notable products in the Royalty Pharma portfolio include the cancer drug Imbruvica, the HIV therapy Prezcobix, and the cystic fibrosis treatment Kalydeco.
Aside from acquiring and managing royalty interests, Royalty Pharma also invests in the development of new therapies. The company partners with pharmaceutical companies and academic institutions to fund research and development programs that may lead to new, innovative treatments. Thus, Royalty Pharma is a key contributor to the advancement of modern medicine.
Royalty Pharma is headquartered in New York City and has additional offices in London, Dublin, and Jersey City. The company went public in June 2020 and is currently listed on the NASDAQ Stock Exchange under the ticker symbol RPRX. With a market capitalization of over $30 billion, Royalty Pharma is considered one of the largest and most successful pharmaceutical companies in the world.
Company Address: 110 East 59th Street New York 10022 NY
Company Phone Number: 883-0200 Stock Exchange / Ticker: NASDAQ RPRX
|
1.8%